Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over ...
DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...
Revenue for Q4 2024 was $1.114 billion, marking an 8% increase year-over-year. Non-GAAP EPS stood at $0.45, missing the estimated $0.50 and reflecting a 10% decline from Q4 2023. Operating income (non ...
Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 ...
Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback